跳至主要内容
临床试验/CTRI/2019/05/019222
CTRI/2019/05/019222招募中1 期

A Comparative study comparing intensified treatment with Moxifloxacin/Pyrazinamide versus standard Anti-tubercular therapy for CNS Tuberculoma

Department of Science and Technology1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2019年5月27日最近更新:

试验速览

阶段
1 期
状态
招募中
入组人数
75
试验地点
1
主要终点
Reduction in size/disappearance of Tuberculoma

研究概览

简要总结

  1. This is a prospective randomised clinical study comprising of 25 patients in each arm using random table method:Group A- 4-drug ATT: INH, Rifampicin, Pyrazinamide, Ethambutol in the 1st 2 months of Intensive phase followed by 2 drugs (INH, Rifampicin) in the maintenance phase. Group B- 5-drug ATT: INH, Rifampicin, Pyrazinamide, Ethambutol and Moxifloxacin in the 1st 2 months of Intensive phase followed by 3 drugs (INH, Rifampicin and Moxifloxacin in the maintenance phase. Group C- 4-drug ATT: INH, Rifampicin, Pyrazinamide, Ethambutol in the 1st 2 months of Intensive phase followed by 3 drugs (INH, Rifampicin, Pyrazinamide) in the maintenance phase. The aims and objectives are to compare the effect of the 3 regimens in the resolution of  Brain Tuberculomas, to check if resolution of Tuberculomas begins faster with 5 drug regime or intensification of the 1st line drugs, to check the time taken for complete resolution of Tuberculomas in the three groups, to assess the post resolution residual damage to the brain between the three groups and to correlate the clinical features, cytokines level and neuroimaging. The recruitment phase of this study is for 18 months followed by 18 months of follow up with visits every 3 months with clinical exams and serial MRI imaging at each visit.

研究设计

研究类型
Interventional
分配方式
Stratified block randomization
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • Clinically and radiologically suspected cases of CNS tuberculoma.

排除标准

  • <18yrs, pregnant, HIV positive,refusal to participate in the study.

结局指标

主要结局

Reduction in size/disappearance of Tuberculoma

时间窗: 3 months, 6 months, 12 months, 18 months

次要结局

  • Improvement in clinical parameters,symptoms and signs like headache,focal deficits and reduction in disability scores.

研究者

申办方类型
Government funding agency

研究点 (1)

Loading locations...

相似试验